SCHEMBL3767455

SCHEMBL3767455

CO/N=C(\C(=O)O)C(=O)CCl

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767458 1.00 TSHR (0.32) TSHR
SCHEMBL5880313 1.00 TSHR (0.32) TSHR
Hydrochloric Acid SCHEMBL5880365 0.98 TSHR (0.31) TSHR
Trimethylammonium SCHEMBL27325918 0.94
SCHEMBL3767653 0.83
SCHEMBL14257118 0.83
SCHEMBL3767656 0.83
SCHEMBL6133165 0.81 TSHR (0.31) TSHR
SCHEMBL3549809 0.81 TSHR (0.31) TSHR
SCHEMBL3549805 0.81 TSHR (0.31) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020028931-A1 Ceftiofur, its intermediate and a process for the preparation of the same AUROBINDO PHARMA LIMITED (IN) 2002-03-07 US claimed
EP-0842937-A2 Process for the preparation of the cephalosporin derivatives cefotaxime and ceftriaxone Hichem Pharma S.p.A. (IT) 1998-05-20 EP claimed
US-4959495-A Process for the preparation of intermediates used to produce aminothiazoloximino cephalosporins AMERICAN CYANAMID COMPANY (US) 1990-09-25 US claimed
EP-0257275-A2 Cephalosporin and penicillin derivatives AMERICAN CYANAMID COMPANY (US) 1988-03-02 EP claimed
US-8212024-B2 crystallizing Ceftiofur sodium directly from the reaction mass; obviates the use of amine, sodium salt of weak acid like sodium 2-ethylhexonate and membrane filtration in Ceftiofur sodium synthesis ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) 2012-07-03 US disclosed
US-7847093-B2 Processes for the preparations of cefepime SANDOZ AG (CH) 2010-12-07 US disclosed
EP-2218723-A2 Processes for the preparations of cefepime Sandoz AG (CH) 2010-08-18 EP disclosed
US-7479556-B2 Process for producing Cefepime and cephalosporin analogues ACS DOBFAR S.P.A. (IT) 2009-01-20 US disclosed
US-7470786-B2 Method for manufacture of ceftriaxone sodium LUPIN LIMITED (IN) 2008-12-30 US disclosed
US-7452990-B2 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc LUPIN LIMITED (IN) 2008-11-18 US disclosed
US-20080221076-A1 Crystalline Sodium Salt of Cephalosporin Antibiotic ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) 2008-09-11 US disclosed
US-20080200670-A1 METHOD FOR THE MANUFACTURE OF CEFTRIAXONE SODIUM LUPIN LIMITED (RESEARCH PARK) (IN) 2008-08-21 US disclosed
US-4927964-A Method for production of 2-oxyimino-3-oxobutyric acids TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1990-05-22 US disclosed
EP-0325183-A2 Method for the production of 2-oxyimino-3-oxobutyric acids Takeda Chemical Industries, Ltd. (JP) 1989-07-26 EP disclosed
EP-0324418-A2 Method for production of t-butyl- 3-oxobutyrates and their use Takeda Chemical Industries, Ltd. (JP) 1989-07-19 EP disclosed
US-4845257-A 4-halogeno-2-oxyimino-3-oxobutyric acids and derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1989-07-04 US disclosed
EP-0257275-A2 Cephalosporin and penicillin derivatives AMERICAN CYANAMID COMPANY (US) 1988-03-02 EP disclosed
EP-0246603-A2 4-Halogeno-2-Oxyimino-3-Oxobutyric acids Takeda Chemical Industries, Ltd. (JP) 1987-11-25 EP disclosed
EP-0223246-A2 New cephem compounds and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-05-27 EP disclosed
US-4166115-A BACTERICIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028931-A1 Ceftiofur, its intermediate and a process for the preparation of the same BLVRB, CBR1, BTD TSHR 510/4885
US-20080200670-A1 METHOD FOR THE MANUFACTURE OF CEFTRIAXONE SODIUM CHAT, TREH, MRPL21 TSHR 3037/4885
US-20080221076-A1 Crystalline Sodium Salt of Cephalosporin Antibiotic SLC5A1, SLC5A2, SHARPIN TSHR 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.